Compare MMA & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMA | SNGX |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 11.2M |
| IPO Year | 2023 | 2006 |
| Metric | MMA | SNGX |
|---|---|---|
| Price | $0.43 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 333.0K | 179.3K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $1.00 |
| 52 Week High | $2.88 | $6.23 |
| Indicator | MMA | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 43.82 |
| Support Level | $0.35 | $1.01 |
| Resistance Level | $0.50 | $1.47 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 36.40 | 42.19 |
Mixed Martial Arts Group Ltd is a technology company operating in the martial arts and combat sports industry. The company operate four core business units: i) TrainAlta: A platform that transforms MMA fans into active participants through structured training programs like the Warrior Training Program, ii) BJJLink: A gym management platform designed for BJJ academies, offering tools for payment processing, marketing, student engagement, and content monetization, iii) Hype: A marketing platform helping gym owners, coaches, and athletes grow revenue from their audiences, iv) MixedMartialArts.com: The go-to resource for MMA news, fighter data, fight schedules, and the legendary Underground forum. Its majority of revenue is in the form of Program revenue, which consists of the license fees.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).